Grifols SA, Barcelona (NASDAQ:GRFS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
A number of other equities research analysts have also issued reports on GRFS. BidaskClub upgraded Grifols SA, Barcelona from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. UBS Group lowered Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research report on Friday, November 24th. Finally, Citigroup began coverage on Grifols SA, Barcelona in a research report on Tuesday, October 31st. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. Grifols SA, Barcelona presently has a consensus rating of “Hold” and an average target price of $24.00.
A number of institutional investors have recently modified their holdings of GRFS. Harding Loevner LP grew its position in Grifols SA, Barcelona by 477.5% in the third quarter. Harding Loevner LP now owns 89,561,714 shares of the biotechnology company’s stock worth $272,368,000 after acquiring an additional 74,051,933 shares during the period. Ameriprise Financial Inc. grew its position in Grifols SA, Barcelona by 14,219.5% in the second quarter. Ameriprise Financial Inc. now owns 1,901,199 shares of the biotechnology company’s stock worth $40,153,000 after acquiring an additional 1,887,922 shares during the period. Westpac Banking Corp purchased a new position in Grifols SA, Barcelona in the third quarter worth approximately $9,767,000. JPMorgan Chase & Co. grew its position in Grifols SA, Barcelona by 13.1% in the second quarter. JPMorgan Chase & Co. now owns 2,178,611 shares of the biotechnology company’s stock worth $46,035,000 after acquiring an additional 252,169 shares during the period. Finally, GABELLI & Co INVESTMENT ADVISERS INC. grew its position in Grifols SA, Barcelona by 795.2% in the third quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 263,175 shares of the biotechnology company’s stock worth $5,761,000 after acquiring an additional 233,775 shares during the period. Institutional investors own 22.50% of the company’s stock.
Grifols SA, Barcelona Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.